Eli Lilly LLY Jardiance — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's jardiance — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's jardiance — revenue?
- Eli Lilly (LLY) reported jardiance — revenue of $1.11B in Q1 2026.
- How has Eli Lilly's jardiance — revenue changed year-over-year?
- Eli Lilly's jardiance — revenue increased by 9.9% year-over-year, from $1.01B to $1.11B.
- What is the long-term trend for Eli Lilly's jardiance — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's jardiance — revenue has grown at a 23.2% compound annual growth rate (CAGR), from $1.49B to $3.43B.
- What does jardiance — revenue mean?
- This metric represents the total gross sales generated from a specific pharmaceutical product line within the company's portfolio. It reflects the market demand, pricing power, and commercial success of the therapeutic agent in its respective treatment category. Tracking this revenue stream is essential for evaluating the product's contribution to overall corporate growth and its lifecycle stage.